Personalis Other Long-Term Assets 2018-2024 | PSNL

Personalis other long-term assets from 2018 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Personalis Annual Other Long-Term Assets
(Millions of US $)
2023 $3
2022 $5
2021 $5
2020 $2
2019 $2
2018 $1
2017 $
Personalis Quarterly Other Long-Term Assets
(Millions of US $)
2024-09-30 $3
2024-06-30 $3
2024-03-31 $3
2023-12-31 $3
2023-09-30 $4
2023-06-30 $4
2023-03-31 $4
2022-12-31 $5
2022-09-30 $5
2022-06-30 $4
2022-03-31 $4
2021-12-31 $5
2021-09-30 $5
2021-06-30 $4
2021-03-31 $2
2020-12-31 $2
2020-09-30 $2
2020-06-30 $2
2020-03-31 $2
2019-12-31 $2
2019-09-30 $2
2019-06-30 $1
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.412B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.441B 7.12
Dr Reddy's Laboratories (RDY) India $11.160B 21.29
BridgeBio Pharma (BBIO) United States $6.858B 0.00
Bausch Health Cos (BHC) Canada $2.354B 1.71
Supernus Pharmaceuticals (SUPN) United States $1.851B 25.20
Amphastar Pharmaceuticals (AMPH) United States $1.501B 9.02
Taysha Gene Therapies (TSHA) United States $0.336B 23.43
Assembly Biosciences (ASMB) United States $0.081B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.008B 0.00
Teligent (TLGT) United States $0.000B 0.00